Charles Schwab Investment Management Inc. Buys 9,780 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Charles Schwab Investment Management Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,783,177 shares of the biopharmaceutical company’s stock after purchasing an additional 9,780 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.40% of Halozyme Therapeutics worth $85,254,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its position in Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after acquiring an additional 251,711 shares during the last quarter. Boston Trust Walden Corp grew its position in Halozyme Therapeutics by 28.0% during the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company’s stock worth $41,790,000 after acquiring an additional 191,465 shares during the last quarter. South Street Advisors LLC bought a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $9,812,000. Hantz Financial Services Inc. bought a new stake in Halozyme Therapeutics during the 3rd quarter worth approximately $9,260,000. Finally, abrdn plc bought a new stake in Halozyme Therapeutics during the 4th quarter worth approximately $6,152,000. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

HALO has been the topic of a number of research analyst reports. Piper Sandler increased their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 0.8 %

NASDAQ:HALO opened at $61.44 on Tuesday. The stock’s fifty day moving average price is $55.70 and its two-hundred day moving average price is $54.68. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market cap of $7.57 billion, a price-to-earnings ratio of 17.91, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,697 shares of company stock worth $1,754,451 in the last quarter. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.